PVI
RARE icon

Pura Vida Investments’s Ultragenyx Pharmaceutical RARE Stock Holding History

Pura Vida Investments’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-39,750
Closed -$2.82M – 86
2016
Q3 		$2.82M Buy
+39,750
New +$2.54M 0.86% 49

Other funds holding RARE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Pura Vida Investments's RARE Position: Q4 2016 in Review

Pura Vida Investments sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2016, closing a stake of 39,750 shares — an estimated $2.82M sold.

Pura Vida Investments first reported a position in RARE in Q3 2016 and held it in 1 quarter. The position peaked at $2.82M in Q3 2016. 174 funds tracked by Wall St. Rank hold RARE as of Q4 2016.

  • Pura Vida Investments reported no remaining Ultragenyx Pharmaceutical position as of Q4 2016 after selling out during the quarter.
  • Pura Vida Investments sold 39,750 Ultragenyx Pharmaceutical shares in Q4 2016, an estimated $2.82M.
  • Pura Vida Investments first reported a position in Ultragenyx Pharmaceutical in Q3 2016 and held it in 1 quarter.
  • Pura Vida Investments's Ultragenyx Pharmaceutical position peaked at $2.82M in Q3 2016.
  • 174 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2016.

Based on Pura Vida Investments's 13F filing for Q4 2016, filed 14 Feb 2017.